carbomycin

Originator

Magnamycin,Pfizer,US,1953

The Uses of carbomycin

Sixteen-membered-ring macrolite antibiotic complex similar to Leucomycin and Erythromycin, produced by Stroptomyces halstedii.

Definition

An antibiotic isolated from products of Strepto- myces halstedii when grown in suitable media by the deep-culture method. It inhibits growth of certain gram-positive bacteria such as staphylo- cocci, pneumococci, and hemolytic streptococci.

Manufacturing Process

A selected strain of Streptomyces halstedii was cultivated in an aqueous nutrient medium under aerobic conditions and the resulting broth containing carbomycin antibiotics was filtered. The solutions was extracted twice at pH 6.5 with one-quarter volume of methyl isobutyl ketone. The combined extracts were concentrated to one-tenth volume under vacuum, and the antibiotics were extracted into water adjusted to a pH of about 2 with sulfuric acid. After adjusting the separated aqueous solution to pH 6.5, the antibiotic was extracted into benzene and the solution was concentrated to a small volume. Addition of hexane resulted in the separation of a solid product containing the benzene complexes of carbomycin A and carbomycin B, present in the fermentation broth.

brand name

Magnamycin (Pfizer).

Therapeutic Function

Antibiotic

Safety Profile

Poison by subcutaneous route. Moderately toxic by intravenous and intramuscular routes. When heated to decomposition it emits toxic fumes of NOx.